5,506 Shares in Palvella Therapeutics, Inc. $PVLA Bought by Penn Capital Management Company LLC

by · The Markets Daily

Penn Capital Management Company LLC acquired a new stake in shares of Palvella Therapeutics, Inc. (NASDAQ:PVLA – Free Report) in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 5,506 shares of the company’s stock, valued at approximately $841,000.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the company. KBC Group NV purchased a new stake in shares of Palvella Therapeutics during the 1st quarter worth about $28,000. Northwestern Mutual Wealth Management Co. bought a new stake in shares of Palvella Therapeutics in the 2nd quarter valued at approximately $35,000. Group One Trading LLC grew its stake in shares of Palvella Therapeutics by 151.5% in the 4th quarter. Group One Trading LLC now owns 332 shares of the company’s stock valued at $35,000 after buying an additional 200 shares in the last quarter. Russell Investments Group Ltd. acquired a new position in Palvella Therapeutics in the third quarter worth approximately $36,000. Finally, Archer Investment Corp acquired a new position in Palvella Therapeutics in the second quarter worth approximately $69,000. Hedge funds and other institutional investors own 40.11% of the company’s stock.

Analyst Ratings Changes

Several brokerages recently weighed in on PVLA. Truist Financial set a $207.00 price objective on shares of Palvella Therapeutics in a research report on Wednesday, August 5th. HC Wainwright restated a “buy” rating and set a $270.00 price target on shares of Palvella Therapeutics in a research note on Wednesday, July 22nd. Stephens restated an “overweight” rating and set a $220.00 price target on shares of Palvella Therapeutics in a report on Thursday, May 21st. Chardan Capital upgraded shares of Palvella Therapeutics to a “strong-buy” rating in a report on Tuesday, July 28th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Palvella Therapeutics in a report on Monday, June 29th. Two equities research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Palvella Therapeutics has a consensus rating of “Buy” and a consensus price target of $209.14.

View Our Latest Analysis on Palvella Therapeutics

Palvella Therapeutics Stock Down 0.2%

Shares of Palvella Therapeutics stock opened at $149.97 on Friday. Palvella Therapeutics, Inc. has a 12-month low of $49.81 and a 12-month high of $161.38. The stock has a 50 day moving average price of $146.01 and a two-hundred day moving average price of $126.90. The stock has a market capitalization of $2.16 billion, a P/E ratio of -31.05 and a beta of -0.17.

Palvella Therapeutics (NASDAQ:PVLA – Get Free Report) last released its quarterly earnings results on Tuesday, August 4th. The company reported ($1.52) EPS for the quarter, missing analysts’ consensus estimates of ($1.17) by ($0.35). Sell-side analysts anticipate that Palvella Therapeutics, Inc. will post -6.36 earnings per share for the current year.

Insider Transactions at Palvella Therapeutics

In related news, COO Kathleen Goin sold 4,302 shares of Palvella Therapeutics stock in a transaction on Wednesday, August 19th. The shares were sold at an average price of $152.21, for a total value of $654,807.42. Following the transaction, the chief operating officer owned 2,154 shares in the company, valued at $327,860.34. This trade represents a 66.64% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 17.20% of the company’s stock.

Palvella Therapeutics Profile

(Free Report)

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.

See Also